@article{5578bdf0449748a6979a1c48100ab8e7,
title = "Reply",
author = "Brown, {David M.}",
note = "Funding Information: Notwithstanding the limitations described in this letter, we firmly believe that the CAPELLA study supports its main conclusion—the lack of clinical benefit induced by anti-PDGFRβ when it is combined with IAI in the general neovascular AMD population. This finding is consistent with prior studies of anti-PDGR/anti-VEGF combination treatment, including studies with the anti-PDGF Fovista (pegpleranib).2 However, we do not exclude the possibility that a benefit from combining anti-PDGF and anti-VEGF treatments may be seen in the specific patient populations suggested by the correspondent. Although Regeneron has discontinued clinical development of rinucumab + aflibercept,3 it is possible that future improvements in our understanding of the role of PDGF in the pathogenesis of CNV in neovascular AMD will elucidate the most appropriate uses of PDGF pathway inhibitors in retina practice. The authors made the following disclosures: D.M.B.: Consultant – Novartis, Stealth, Adverum, Regeneron, Boehringer Ingelheim, Optos, Bayer, Apellis, Ocular Therapeutix, Kodiak, Senju, Chengdu Kanghong Biotechnology, Lineage (Biotime), Genentech, Annexon, Heidelberg, Celltrion; Grants – Novartis, Stealth, Adverum, Regeneron, Boehringer Ingelheim, Optos, Apellis, Kodiak, Senju, Chengdu Kanghong Biotechnology, Genentech, Heidelberg; all outside the submitted work.",
year = "2021",
month = oct,
doi = "10.1016/j.ophtha.2021.03.039",
language = "English (US)",
volume = "128",
pages = "e70",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier",
number = "10",
}